June 20 (Reuters) - Novo Nordisk A/S:
* ORAL SEMAGLUTIDE SHOWS STATISTICALLY SIGNIFICANTLY GREATER REDUCTIONS IN HBA1C AND WEIGHT COMPARED TO VICTOZA AND SITAGLIPTIN IN PIONEER 4 AND 7 TRIALS
* PIONEER 4 ACHIEVED ITS PRIMARY OBJECTIVE ACCORDING TO PRIMARY STATISTICAL APPROACH BY DEMONSTRATING A NON-INFERIOR REDUCTION IN HBA1C
* ORAL SEMAGLUTIDE PROVIDED STATISTICALLY SIGNIFICANT AND SUPERIOR REDUCTIONS IN HBA1C AND WEIGHT COMPARED TO PLACEBO.
* PLANS TO REPORT PIONEER 3 TRIAL COMPARING 3, 7 AND 14 MG ORAL SEMAGLUTIDE WITH 100 MG SITAGLIPTIN BEFORE END OF Q2 OF 2018 Source text for Eikon: Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.
